CalciMedica, a clinical-stage biopharma company pioneering therapeutics targeting calcium release-activated calcium (CRAC) channels, has demonstrated a scientifically differentiated platform with Auxora leading multiple Phase 2 trials for inflammatory diseases. Despite its technological promise, the company continues to grapple with significant net losses and cash burn fueled by ongoing clinical development costs. Its capital structure, reliant on milestone-based debt tranches and equity offerings, underscores funding constraints that interplay tightly with clinical progress. Upcoming Phase 3 milestones and financing events warrant close attention to gauge sustainability on its path toward potential commercialization.